18 January 2023 - Ascentage Pharma and Innovent Biologics today announced that the novel drug olverembatinib has been included into the China 2022 National Reimbursement Drug List for the treatment of T315I mutant chronic-phase chronic myeloid leukaemia and accelerated phase CML.
The new version of the National Reimbursement Drug List will take effect on 1 March 2023.